Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map database

16 Sept 2018

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is the most main subtype in non-Hodgkin lymphoma. After chemotherapy, about 30% of patients with DLBCL develop resistance and relapse. This study was to identify potential therapeutic drugs for DLBCL using the bioinformatics method. The differentially expressed genes (DEGs) between DLBCL and non-cancer samples were downloaded from the Cancer Genome Atlas (TCGA) and the Gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 14-3-3 protein interactions
Share to Bioinformatics and Genomic Networks
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30244948
DOI: 10.1016/j.prp.2018.09.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of potential drugs for diffuse large b-cell lymphoma based on bioinformatics and Connectivity Map databasePMID 30244948Read ↗

RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cellsSemantic proximity Read ↗

Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphomaSemantic proximity Read ↗

Comprehensive characterization�of driver genes in diffuse large B�cell lymphomaSemantic proximity Read ↗

Identification of a 16-MTGs Prognostic Signature in Diffuse large B-cell lymphomaSemantic proximity Read ↗

Decipherment of disulfidptosis-related mutation profile, chemosensitivity, and prognosis in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Identification of Significant Genes and Therapeutic Agents for Breast Cancer by Integrated BioinformaticsSemantic proximity Read ↗

Screening and identifcation of differentially expressed microRNAs in diffuse large B-cell lymphoma based on microRNA microarraySemantic proximity Read ↗

Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.Semantic proximity Read ↗

DCZ0014, A Novel Compound in the Therapy of Diffuse Large B-Cell Lymphoma via the B Cell Receptor Signaling PathwaySemantic proximity Read ↗

Mechanisms of chemoresistance in diffuse large B‑cell lymphoma and novel therapeutic strategies (Review).Semantic proximity Read ↗

Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancerSemantic proximity Read ↗

Multiple Omics Analysis Reveals E2F5 Predict Prognostic Biomarker in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.